https://www.qureight.com 2026-03-17T10:44:44+00:00 weekly 1 https://www.qureight.com/about 2026-02-24T14:26:46+00:00 monthly 0.5 https://www.qureight.com/news 2026-02-24T14:26:51+00:00 monthly 0.5 https://www.qureight.com/news/qureight-today-announces-that-we-have-gained-iso13485-certification 2026-02-24T14:27:17+00:00 monthly 0.3 https://www.qureight.com/news/qureight-today-announces-the-appointment-of-dr-xose-fernandez-to-its-scientific-advisory-board 2026-02-24T14:27:05+00:00 monthly 0.3 https://www.qureight.com/news/qureight-is-partnering-with-patientmpower-to-reveal-ai-insights-for-improved-ild-care 2026-02-24T14:27:24+00:00 monthly 0.3 https://www.qureight.com/news/dr-pilar-rivera-ortega-joins-qureight-s-scientific-advisory-board 2026-02-24T14:27:11+00:00 monthly 0.3 https://www.qureight.com/news/qureight-collaborates-with-astrazeneca-on-lung-disease-research 2026-02-24T14:27:04+00:00 monthly 0.3 https://www.qureight.com/news/qureight-and-vicore-pharma-release-results-characterising-lung-disease-patients-who-may-be-more-responsive-to-c21-treatment 2026-02-24T14:27:11+00:00 monthly 0.3 https://www.qureight.com/news/claus-torp-jensen-appointed-as-chairperson-of-the-qureight-board 2026-02-24T14:27:19+00:00 monthly 0.3 https://www.qureight.com/news/appointment-of-javier-alvarez-valle-to-qureight-scientific-advisory-board 2026-02-24T14:27:29+00:00 monthly 0.3 https://www.qureight.com/news/qureight-partners-with-king-faisal-specialist-hospital-and-research-centre-for-innovative-lung-transplant-research-pilot 2026-02-24T14:27:12+00:00 monthly 0.3 https://www.qureight.com/news/qureight-appoints-dr-simon-walsh-as-chief-scientific-officer 2026-02-24T14:27:06+00:00 monthly 0.3 https://www.qureight.com/news/qureight-appoints-dr-steven-bishop-as-chief-data-officer 2026-02-24T14:27:34+00:00 monthly 0.3 https://www.qureight.com/news/qureight-joins-osic-and-gains-access-to-world-s-largest-curated-data-repository-for-ilds 2026-02-24T14:27:20+00:00 monthly 0.3 https://www.qureight.com/news/summer-news-and-updates-from-the-qureight-team 2026-02-24T14:27:25+00:00 monthly 0.3 https://www.qureight.com/news/automated-airway-model-in-ipf-ers-abstract 2026-02-24T14:27:25+00:00 monthly 0.3 https://www.qureight.com/news/venturing-forth-cambridge-judge-business-school 2026-02-24T14:27:29+00:00 monthly 0.3 https://www.qureight.com/news/addressing-inequalities-in-healthcare 2026-02-24T14:27:09+00:00 monthly 0.3 https://www.qureight.com/news/automated-cohort-selection-ers-abstract 2026-02-24T14:27:18+00:00 monthly 0.3 https://www.qureight.com/news/cambridge-tech-podcast 2026-02-24T14:27:05+00:00 monthly 0.3 https://www.qureight.com/news/astrazeneca-adopts-qureight-platform-for-ipf-research 2026-02-24T14:27:32+00:00 monthly 0.3 https://www.qureight.com/news/glpg1205-ers-abstract 2026-02-24T14:27:14+00:00 monthly 0.3 https://www.qureight.com/news/cambridge-angels-5-questions 2026-02-24T14:27:17+00:00 monthly 0.3 https://www.qureight.com/news/imaging-adds-to-mortality-prediction-in-ipf-ats-abstract 2026-02-24T14:27:30+00:00 monthly 0.3 https://www.qureight.com/news/automated-vascular-and-fibrotic-segmentations-associated-with-ipf-mortality-ats-abstract 2026-02-24T14:27:33+00:00 monthly 0.3 https://www.qureight.com/news/uktn-pitching-to-investors 2026-02-24T14:27:08+00:00 monthly 0.3 https://www.qureight.com/news/8-questions-by-playfair 2026-02-24T14:27:13+00:00 monthly 0.3 https://www.qureight.com/news/characterisation-of-high-responders-in-the-air-c21-vicore-study-ers-abstract 2026-02-24T14:27:07+00:00 monthly 0.3 https://www.qureight.com/news/sifted-series-a-announcement 2026-02-24T14:27:22+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-based-segmentation-of-computed-tomography-scans-predicts-disease-progression-and-mortality-in-idiopathic-pulmonary 2026-02-24T14:27:23+00:00 monthly 0.3 https://www.qureight.com/news/an-autumn-team-update-from-qureight 2026-02-24T14:27:23+00:00 monthly 0.3 https://www.qureight.com/news/cancer-specialists-kent-yip-john-conibear-are-joining-the-qureight-scientific-advisory-board 2026-02-24T14:27:22+00:00 monthly 0.3 https://www.qureight.com/news/unravelling-the-most-complex-disease-challenges-in-history-how-ai-startups-are-changing-drug-discovery 2026-02-24T14:27:10+00:00 monthly 0.3 https://www.qureight.com/news/qureight-achieves-iso-27001-certification-gold-standard-for-data-security-in-healthcare 2026-02-24T14:27:16+00:00 monthly 0.3 https://www.qureight.com/news/qureight-and-avalyn-launch-strategic-partnership-in-progressive-pulmonary-fibrosis 2026-02-24T14:27:27+00:00 monthly 0.3 https://www.qureight.com/news/qureight-and-avalyn-launch-strategic-partnership-in-pulmonary-fibrosis 2026-02-24T14:27:28+00:00 monthly 0.3 https://www.qureight.com/news/qureight-core-imaging-platform-deployed-within-vicore-phase-2b-aspire-study-of-buloxibutid-for-ipf 2026-02-24T14:27:20+00:00 monthly 0.3 https://www.qureight.com/news/qureight-tech-deployed-in-lung-fibrosis-clinical-trial 2026-02-24T14:27:07+00:00 monthly 0.3 https://www.qureight.com/news/vicore-pharma-to-track-lung-fibrosis-trial-with-qureight-s-ai-powered-imaging-platform 2026-02-24T14:27:32+00:00 monthly 0.3 https://www.qureight.com/news/starting-2025-on-a-high 2026-02-24T14:27:17+00:00 monthly 0.3 https://www.qureight.com/news/qureight-appoints-patrick-driscoll-as-chief-financial-officer 2026-02-24T14:27:23+00:00 monthly 0.3 https://www.qureight.com/news/qureight-and-remedy-cell-partner-to-integrate-deep-learning-platform-into-phase-1b-study-of-rc-0315-in-ipf 2026-02-24T14:27:19+00:00 monthly 0.3 https://www.qureight.com/news/qureight-and-remedy-cell-to-validate-rc-0315-in-phase-ib-trial-for-ipf 2026-02-24T14:27:27+00:00 monthly 0.3 https://www.qureight.com/news/the-role-of-nhs-big-data-and-ai-technology-in-unlocking-the-future-of-lung-and-heart-disease-treatment 2026-02-24T14:27:12+00:00 monthly 0.3 https://www.qureight.com/news/qureight-board-of-directors-elects-dr-neil-johnston-to-the-board-as-non-executive-chair 2026-02-24T14:27:06+00:00 monthly 0.3 https://www.qureight.com/news/appointment-of-dr-paul-ford-md-phd-as-senior-clinical-development-advisor 2026-02-24T14:27:08+00:00 monthly 0.3 https://www.qureight.com/news/how-is-deep-learning-imaging-advancing-drug-discovery-for-fibrosis 2026-02-24T14:27:27+00:00 monthly 0.3 https://www.qureight.com/news/qureight-showcases-the-power-of-ai-driven-image-analytics-across-eight-presentations-at-the-2025-ats-international-conference 2026-02-24T14:27:35+00:00 monthly 0.3 https://www.qureight.com/news/rein-therapeutics-and-qureight-ltd-announce-planned-integration-of-deep-learning-platform-for-phase-2-trial-of-lti-03-in-patient 2026-02-24T14:27:18+00:00 monthly 0.3 https://www.qureight.com/news/rein-therapeutics-and-qureight-broaden-life-science-collaboration 2026-02-24T14:27:34+00:00 monthly 0.3 https://www.qureight.com/news/qureight-partners-with-cumberland-pharmaceuticals-to-advance-innovative-idiopathic-pulmonary-fibrosis-treatment-research 2026-02-24T14:27:28+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-based-disease-severity-biomarkers-on-ct-posthoc-analysis-in-a-phase-2a-placebo-controlled-study-of-env-101-in-subj 2026-02-24T14:27:24+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-based-quantitative-ct-and-ct-phenotype-classification-independently-predict-mortality-in-idiopathic-pulmonary-fibr 2026-02-24T14:27:05+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-based-quantitative-ct-and-proteomics-for-predicting-outcomes-in-idiopathic-pulmonary-fibrosis 2026-02-24T14:27:33+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-based-short-term-disease-progression-evaluation-supersedes-automated-baseline-ct-phenotype-in-predicting-outcomes- 2026-02-24T14:27:35+00:00 monthly 0.3 https://www.qureight.com/news/dose-dependent-change-of-inhaled-pirfenidone-seen-in-lung-volume-and-fibrosis-quantification-in-patients-with-ipf-a-deep-learnin 2026-02-24T14:27:34+00:00 monthly 0.3 https://www.qureight.com/news/monte-carlo-external-control-arm-generation-utilising-real-world-patient-data-and-deep-learning-based-quantitative-ct-metrics-de 2026-02-24T14:27:13+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-quantitative-computed-tomography-analysis-in-the-australian-idiopathic-pulmonary-fibrosis-registry 2026-02-24T14:27:28+00:00 monthly 0.3 https://www.qureight.com/news/the-potential-for-deep-learning-technology-in-clinical-trials 2026-02-24T14:27:36+00:00 monthly 0.3 https://www.qureight.com/news/qureight-s-synthetic-study-arms-validate-clinical-efficacy-in-pioneering-rare-lung-disease-treatment 2026-02-24T14:27:08+00:00 monthly 0.3 https://www.qureight.com/news/qureight-analyses-of-insilico-medicine-s-phase-iia-rentosertib-data-support-preliminary-efficacy-results-and-future-trial-expans 2026-02-24T14:27:21+00:00 monthly 0.3 https://www.qureight.com/news/qureight-s-ai-3d-imaging-platform-to-support-calluna-pharma-s-phase-2-aurora-study-of-cal101-in-idiopathic-pulmonary-fibrosis-ip 2026-02-24T14:27:36+00:00 monthly 0.3 https://www.qureight.com/news/qureight-appoints-craig-rhodes-as-head-of-partnerships-to-lead-on-pharma-relationship-management 2026-02-24T14:27:13+00:00 monthly 0.3 https://www.qureight.com/news/appointment-of-professor-tamera-corte-to-qureight-s-scientific-advisory-committee 2026-02-24T14:27:10+00:00 monthly 0.3 https://www.qureight.com/news/qureight-has-major-presence-at-2025-ers-congress-to-highlight-how-advanced-imaging-biomarkers-and-ai-are-transforming-interstiti 2026-02-24T14:27:14+00:00 monthly 0.3 https://www.qureight.com/news/combined-deep-learning-algorithms-demonstrate-that-both-computed-tomography-phenotype-and-anatomical-biomarkers-are-predictive-o 2026-02-24T14:27:20+00:00 monthly 0.3 https://www.qureight.com/news/pulmonary-blood-volumes-on-ct-predict-residual-pulmonary-hypertension-post-pulmonary-endarterectomy 2026-02-24T14:27:26+00:00 monthly 0.3 https://www.qureight.com/news/qureight-vascul8-model-for-pulmonary-vascular-disorders-validated-in-peer-reviewed-study-offering-potential-to-improve-treatment 2026-02-24T14:27:15+00:00 monthly 0.3 https://www.qureight.com/news/the-role-of-quantitative-ct-in-the-prognostication-and-monitoring-of-systemic-autoimmune-rheumatic-disease-related-interstitial-lung-disease 2026-02-24T14:27:20+00:00 monthly 0.3 https://www.qureight.com/news/comparison-of-the-baseline-clinical-and-hrct-characteristics-of-insilico-s-ism001-055-phase-2a-trial-cohort-in-china-with-real-world-ipf-datasets 2026-02-24T14:27:26+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-analysis-of-serial-ct-scans-correlates-with-changes-in-how-patients-feel-function-and-survive-in-fibrotic-interstitial-lung-disease 2026-02-24T14:27:15+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-based-airway-and-vessel-volume-are-associated-with-increased-risk-of-mortality-in-connective-tissue-disease-related-interstitial-lung-disease 2026-02-24T14:27:10+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-based-fibrosis-and-ground-glass-opacification-quantification-with-proteomic-biomarkers-for-outcome-prediction-in-idiopathic-pulmonary-fibrosis 2026-02-24T14:27:09+00:00 monthly 0.3 https://www.qureight.com/news/deep-learning-based-image-quantification-of-ctpa-to-phenotype-pulmonary-arterial-hypertension 2026-02-24T14:27:24+00:00 monthly 0.3 https://www.qureight.com/news/longitudinal-changes-in-quantitative-imaging-biomarkers-are-associated-with-increased-risk-of-mortality-in-connective-tissue-disease-related-interstitial-lung-disease 2026-02-24T14:27:15+00:00 monthly 0.3 https://www.qureight.com/news/pmg1015-demonstrates-a-well-tolerated-safety-profile-and-favorable-fvc-changes-after-12-weeks-of-treatment-in-ipf-patients 2026-02-24T14:27:31+00:00 monthly 0.3 https://www.qureight.com/news/qureight-appoints-dr-steven-bishop-as-chief-medical-officer 2026-02-24T14:27:12+00:00 monthly 0.3 https://www.qureight.com/news/qureight-appoints-rebecca-simmons-as-chief-operating-officer 2026-02-24T14:27:16+00:00 monthly 0.3 https://www.qureight.com/news/meet-jeremy-from-musician-to-front-end-engineer-at-qureight 2026-03-11T13:40:30+00:00 weekly 0.3 https://www.qureight.com/news/meet-sammy-clinical-project-manager-at-qureight 2026-03-18T11:17:36+00:00 weekly 0.3 https://www.qureight.com/news/meet-rebecca-building-the-data-foundations-behind-ai-powered-clinical-trials 2026-03-25T11:18:42+00:00 weekly 0.3 https://www.qureight.com/news/meet-richard-building-partnerships-for-ai-powered-clinical-trials 2026-04-01T11:28:18+01:00 daily 0.3 https://www.qureight.com/products 2026-03-17T10:37:59+00:00 weekly 0.5 https://www.qureight.com/products/global-imaging-cro-services 2026-03-19T14:47:45+00:00 weekly 0.3 https://www.qureight.com/products/ai-powered-endpoints-and-analytics 2026-03-17T10:38:06+00:00 weekly 0.3 https://www.qureight.com/products/data-science-products 2026-03-17T10:38:00+00:00 weekly 0.3 https://www.qureight.com/careers 2026-04-01T13:53:22+01:00 daily 0.5 https://www.qureight.com/contact 2026-03-07T15:00:11+00:00 weekly 0.5 https://www.qureight.com/trust-centre 2026-02-24T14:26:42+00:00 monthly 0.5 https://www.qureight.com/trust-centre/terms-of-use-website 2026-02-24T14:26:53+00:00 monthly 0.3 https://www.qureight.com/trust-centre/terms-of-use-platform 2026-02-24T14:26:53+00:00 monthly 0.3 https://www.qureight.com/trust-centre/acceptable-use-notice 2026-02-24T14:26:53+00:00 monthly 0.3 https://www.qureight.com/trust-centre/privacy-notice 2026-02-24T14:26:53+00:00 monthly 0.3 https://www.qureight.com/trust-centre/cookie-policy 2026-02-24T14:26:53+00:00 monthly 0.3